// App-Quantinova.ai

: High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI

Researchers

Presenter

  • R De Caterina

Principal Investigators

  • J L Lopez Sendon

  • S Mehta

  • G Opolski

  • J Oldgren

  • P G Steg

  • S Hohnloser

  • G Y H Lip

  • T Kimura

  • M Nordaby

Medical Centers

  • G. DAnnunzio University, Chieti, Italy

  • University Hospital La Paz, Madrid, Spain

  • Medical University of Warsaw, Warsaw, Poland

  • Uppsala University Hospital, Uppsala, Sweden

  • GH Bichat Claude Bernard, Paris, France

  • Goethe University, Frankfurt, Germany

  • Birmingham Children's Hospital, Birmingham, United Kingdom

  • Kyoto University, Kyoto, Japan

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

Locations

  • Italy

  • Spain

  • Canada

  • Poland

  • Sweden

  • France

  • Germany

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • Body mass index

Drug/Treatment

  • Clopidogrel bisulfate

  • Pradax

  • Ticagrelor

  • Warfarin

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved